Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trevena Inc TRVN

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).


OTCPK:TRVN - Post by User

Bullboard Posts
Post by GolongGekkoon Feb 16, 2017 12:15pm
81 Views
Post# 25855657

Institutional BUYING - FYI

Institutional BUYING - FYIA number of institutional investors have recently modified their holdings of TRVN. GSA Capital Partners LLP acquired a new position in shares of Trevena during the second quarter worth $344,000. Bourgeon Capital Management LLC raised its position in shares of Trevena by 70.8% in the second quarter. Bourgeon Capital Management LLC now owns 54,300 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 22,500 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Trevena by 153.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 127,334 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 77,100 shares during the period. Alps Advisors Inc. raised its position in shares of Trevena by 28.3% in the second quarter. Alps Advisors Inc. now owns 73,294 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 16,169 shares during the period. Finally, Northpointe Capital LLC raised its position in shares of Trevena by 92.6% in the second quarter. Northpointe Capital LLC now owns 379,186 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 182,261 shares during the period. 74.06% of the stock is owned by institutional investors and hedge funds.
Bullboard Posts